Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Foghorn Therapeutics (FHTX) over the last 6 years, with Sep 2025 value amounting to -$18.9 million.

  • Foghorn Therapeutics' Free Cash Flow rose 11.51% to -$18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.9 million, marking a year-over-year increase of 14.45%. This contributed to the annual value of -$101.3 million for FY2024, which is 15.10% up from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Free Cash Flow is -$18.9 million, which was up 10.28% from -$21.0 million recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Free Cash Flow ranged from a high of $271.3 million in Q1 2022 and a low of -$32.6 million during Q2 2023.
  • For the 3-year period, Foghorn Therapeutics' Free Cash Flow averaged around -$25.9 million, with its median value being -$25.6 million (2024).
  • As far as peak fluctuations go, Foghorn Therapeutics' Free Cash Flow tumbled by 668.14% in 2021, and later surged by 1,187.72% in 2022.
  • Quarterly analysis of 5 years shows Foghorn Therapeutics' Free Cash Flow stood at $11.8 million in 2021, then plummeted by 347.36% to -$29.2 million in 2022, then climbed by 5.53% to -$27.6 million in 2023, then climbed by 9.36% to -$25.0 million in 2024, then rose by 11.51% to -$18.9 million in 2025.
  • Its Free Cash Flow stands at -$18.9 million for Q3 2025, versus -$21.0 million for Q2 2025 and -$24.0 million for Q1 2025.